Filing Details
- Accession Number:
- 0001640455-18-000039
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-03-12 19:06:07
- Reporting Period:
- 2018-03-08
- Accepted Time:
- 2018-03-12 19:06:07
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1640455 | Jounce Therapeutics Inc. | JNCE | () | 4 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1340881 | C Kimberlee Drapkin | C/O Jounce Therapeutics, Inc. 780 Memorial Drive Cambridge MA 02139 | Cfo And Treasurer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2018-03-08 | 3,759 | $0.48 | 5,267 | No | 4 | M | Direct | |
Common Stock | Disposition | 2018-03-08 | 5,267 | $25.01 | 0 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Disposition | 2018-03-08 | 3,759 | $0.00 | 3,759 | $0.48 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
3,016 | 2024-01-27 | No | 4 | M | Direct |
Footnotes
- The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 8, 2017. The Reporting Person exercised no discretion with respect to these transactions.
- Represents the weighted average share price of an aggregate total of 5,267 shares sold in the price range of $25.00 to $25.24 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission Staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- The option shares vested and became exercisable in 12 monthly installments from October 9, 2013.